Therapy Areas: Hereditary Disorders
ELITechGroup Biomedical Systems Launches Macroduct Advanced–A Sweat Induction and Collection Method Cleared by the FDA
21 August 2018 - - US-based sweat testing specialist ELITechGroup Biomedical Systems has release the new FDA-cleared Macroduct Advanced Sweat Collection System, the company said.

Features of the new Macroduct Advanced include a touch screen user interface with built-in step-by-step graphical instructions that further standardize pilocarpine iontophoresis and sweat collection for optimum results.

In addition, the revised shape of electrodes and Macroduct collector offer greater convenience when working with neonates and toddlers with small limbs.

This system truly is meant to enhance laboratory workflow in meeting protocols and traceability requirements with flexible options for data management.

ELITechGroup Biomedical Systems is in the laboratory diagnosis of cystic fibrosis with the proven products for sweat stimulation, collection, and analysis.

The company is also a key player in supporting global laboratories with the world's most advanced cytocentrifuge rotor, slide stainers, and osmometers.
Login
Username:

Password:


Related Headlines

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy

Markels Named to Arcturus Therapeutics Board of Directors

SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis

Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638

Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera